Nicolien T. van Ravesteyn
Nicolien T. van Ravesteyn
Erasmus MC
Потвърден имейл адрес: erasmusmc.nl
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms
JS Mandelblatt, KA Cronin, S Bailey, DA Berry, HJ De Koning, G Draisma, ...
Annals of internal medicine 151 (10), 738-747, 2009
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis
HD Nelson, B Zakher, A Cantor, R Fu, J Griffin, ES O'Meara, DSM Buist, ...
Annals of internal medicine 156 (9), 635-648, 2012
Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies
JS Mandelblatt, NK Stout, CB Schechter, JJ Van Den Broek, DL Miglioretti, ...
Annals of internal medicine 164 (4), 215-225, 2016
Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012
SK Plevritis, D Munoz, AW Kurian, NK Stout, O Alagoz, AM Near, SJ Lee, ...
Jama 319 (2), 154-164, 2018
Interpreting overdiagnosis estimates in population-based mammography screening
R de Gelder, EAM Heijnsdijk, NT van Ravesteyn, J Fracheboud, ...
Epidemiologic reviews 33 (1), 111-121, 2011
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts
BL Sprague, NK Stout, C Schechter, NT Van Ravesteyn, M Cevik, ...
Annals of internal medicine 162 (3), 157-166, 2015
Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review
EEL Jansen, N Zielonke, A Gini, A Anttila, N Segnan, Z Vokó, U Ivanuš, ...
European journal of cancer 127, 207-223, 2020
Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study
DL Miglioretti, J Lange, JJ Van Den Broek, CI Lee, NT Van Ravesteyn, ...
Annals of internal medicine 164 (4), 205-214, 2016
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality
D Munoz, AM Near, NT Van Ravesteyn, SJ Lee, CB Schechter, O Alagoz, ...
Journal of the National Cancer Institute 106 (11), dju289, 2014
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits
I Lansdorp-Vogelaar, R Gulati, AB Mariotto, CB Schechter, ...
Annals of internal medicine 161 (2), 104-112, 2014
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography
NK Stout, SJ Lee, CB Schechter, K Kerlikowske, O Alagoz, D Berry, ...
Journal of the National Cancer Institute 106 (6), dju092, 2014
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk
NT Van Ravesteyn, DL Miglioretti, NK Stout, SJ Lee, CB Schechter, ...
Annals of internal medicine 156 (9), 609-617, 2012
Impact of colorectal cancer screening on cancer-specific mortality in Europe: a systematic review
A Gini, EEL Jansen, N Zielonke, RGS Meester, C Senore, A Anttila, ...
European Journal of Cancer 127, 224-235, 2020
Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: collaborative modeling of screening outcomes
A Trentham-Dietz, K Kerlikowske, NK Stout, DL Miglioretti, CB Schechter, ...
Annals of internal medicine 165 (10), 700-712, 2016
Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review
N Zielonke, A Gini, EEL Jansen, A Anttila, N Segnan, A Ponti, P Veerus, ...
European journal of cancer 127, 191-206, 2020
The impact of the Covid-19 pandemic on breast cancer early detection and screening
JD Figueroa, E Gray, N Pashayan, S Deandrea, A Karch, DB Vale, ...
Preventive medicine 151, 106585, 2021
Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States
NT Van Ravesteyn, CB Schechter, AM Near, EAM Heijnsdijk, MA Stoto, ...
Cancer epidemiology, biomarkers & prevention 20 (1), 112-122, 2011
The potential of breast cancer screening in Europe
N Zielonke, LM Kregting, EAM Heijnsdijk, P Veerus, S Heinävaara, ...
International journal of cancer 148 (2), 406-418, 2021
Effects of cancer screening restart strategies after COVID-19 disruption
LM Kregting, S Kaljouw, L de Jonge, EEL Jansen, EFP Peterse, ...
British journal of cancer 124 (9), 1516-1523, 2021
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis
NT Van Ravesteyn, NK Stout, CB Schechter, EAM Heijnsdijk, O Alagoz, ...
Journal of the National Cancer Institute 107 (7), djv103, 2015
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20